Revenue Recognition

3 Months Ended

Mar. 31, 2018

9. Revenue Recognition

Our source of product revenue for three months ended March 31, 2018, consists of sales of HEPLISAV-B in the U.S. The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2018 (in thousands):

	Chargebacks, discounts and other fees			Returns		Total
Balance at December 31, 2017	$	-		$	-	$	-
Provision related to current period sales		73			13		86
Credit or payments made during the period		(1	)		-		(1	)
Balance at March 31, 2018	$	72		$	13	$	85

At March 31, 2018, $66,000 of these reserves were classified as reductions of accounts receivable on the condensed consolidated balance sheets and $19,000 were classified as accrued liabilities.